DNDi Joins WIPO Open Innovation Platform But Calls for More Ambitious Provisions for Innovation and Access

[Geneva, Switzerland – October 26, 2011]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the World Intellectual Property Organization (WIPO) initiative to create an open innovation platform – in the form of a searchable public database – to make intellectual property (IP), including compounds and regulatory data, for neglected disease innovation available for licensing. The initiative, called Re:Search, is being launched today in Geneva.

DNDi Intellectual Property Workshop

[December 4, 2010]
New Delhi, India
In collaboration with partners from the Program on Global health and Technology Access of Duke University, DNDi organized a workshop on intellectual property and open innovation on 4th December 2010 in New Delhi, India. The workshop gathered around 50 participants including DNDi partners, representatives of Indian civil society and DNDi staff.

World Health Assembly: MSF and DNDi call on World Health Organization Member States to include access to diagnosis and treatment in the resolution on Chagas disease

[Geneva, Switzerland – May 17, 2010]
The Resolution ‘Chagas Disease: Control and Elimination’ to be adopted by the WHO is a step in the right direction but lacks essential elements
At the ‘World Health Assembly’ (May 17-22, 2010) in Geneva, the resolution ‘Chagas Disease: Control and Elimination’ is about to be adopted by the World Health Organization (WHO). Although this is a step in the right direction, the resolution lacks essential elements. Médecins Sans Frontières/Doctors Without Borders (MSF) and Drugs for Neglected Disease initiative (DNDi) call on WHO Member States to include in the resolution the integration of treatment and diagnosis at the primary healthcare level and increased efforts in research and development.

Cohred & Nepad Meeting: Strengthening Pharmaceutical Innovation in Africa

[February 18-20, 2010]
Pretoria, South Africa
The meeting addressed the problems and challenges faced by African countries in their quest to increase access to medicines and research for innovative products, and to stimulate production of medicines in Africa. DNDi presented the background need for strengthened regulatory capacity in Africa in the Plenary session, and also held a Regulatory workshop. DNDi and the George Institute took advantage  of this meeting to launch their joint report: “Registering New Drugs: The African context”.